Discusses a phase I clinical trial of a gene therapy approach using autologous rheumatoid arthritis (RA) synovial fibroblasts transfected with interleukin-1Ra retrovirus. Disadvantages of biological therapies for RA; Advantages of gene therapy approach; Assessment of the safety of ex vivo gene therapy; Potential of somatic gene transfer as a therapeutic strategy.